CAPTRUST Financial Advisors
AKBA icon

CAPTRUST Financial Advisors’s Akebia Therapeutics AKBA Stock Holding History

CAPTRUST Financial Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,042
Closed -$27.4K – 2740
2025
Q3 		$27.4K Buy
+10,042
New +$33.4K ﹤0.01% 2593
2025
Q2 		– Sell
-32,663
Closed -$62.7K – 2510
2025
Q1 		$62.7K Buy
32,663
+19,952
+157% +$40.7K ﹤0.01% 2270
2024
Q4 		$24.2K Buy
+12,711
New +$22.1K ﹤0.01% 2269
2022
Q2 		– Sell
-10
Closed – – 4918
2022
Q1 		$0 Hold
10
– – ﹤0.01% 4901
2021
Q4 		$0 Hold
10
– – ﹤0.01% 4753
2021
Q3 		$0 Sell
10
-357
-97% -$1.02K ﹤0.01% 4622
2021
Q2 		$1K Sell
367
-95
-21% -$320 ﹤0.01% 4295
2021
Q1 		$2K Buy
+462
New +$1.66K ﹤0.01% 4003

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CAPTRUST Financial Advisors's AKBA Position: Q4 2025 in Review

CAPTRUST Financial Advisors sold out of Akebia Therapeutics (AKBA) in Q4 2025, closing a stake of 10,042 shares — an estimated $27.4K sold.

CAPTRUST Financial Advisors first reported a position in AKBA in Q1 2021 and held it in 8 quarters. The position peaked at $62.7K in Q1 2025. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

  • CAPTRUST Financial Advisors reported no remaining Akebia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 10,042 Akebia Therapeutics shares in Q4 2025, an estimated $27.4K.
  • CAPTRUST Financial Advisors first reported a position in Akebia Therapeutics in Q1 2021 and held it in 8 quarters.
  • CAPTRUST Financial Advisors's Akebia Therapeutics position peaked at $62.7K in Q1 2025.
  • 165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on CAPTRUST Financial Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.